Gabapentin Enacarbil Extended ‐Release for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled, Multisite Trial assessing Efficacy and Safety

ConclusionOverall, GE ‐XR at 600 mg BID did not reduce alcohol consumption or craving in individuals with AUD. It is possible that, unlike the IR formulation of gabapentin, which showed efficacy in smaller Phase 2 trials at a higher dose, GE‐XR is not effective in treating AUD, at least not at doses approved by the F DA for treating other medical conditions.This article is protected by copyright. All rights reserved.

Source: Alcoholism: Clinical and Experimental Research - November 7, 2018 Category: Addiction Authors: Daniel E. Falk, Megan L. Ryan, Joanne B. Fertig, Eric G. Devine, Ricardo Cruz, E. Sherwood Brown, Heather Burns, Ihsan M. Salloum, D. Jeffrey Newport, John Mendelson, Gantt Galloway, Kyle Kampman, Catherine Brooks, Alan I. Green, Mary F. Bru Tags: Original Research Article Source Type: research